Annual Cash & Cash Equivalents
$68.80 M
-$30.16 M-30.47%
December 31, 2023
Summary
- As of February 7, 2025, VYGR annual cash & cash equivalents is $68.80 million, with the most recent change of -$30.16 million (-30.47%) on December 31, 2023.
- During the last 3 years, VYGR annual cash & cash equivalents has fallen by -$35.64 million (-34.12%).
- VYGR annual cash & cash equivalents is now -41.41% below its all-time high of $117.43 million, reached on December 31, 2021.
Performance
VYGR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$112.53 M
+$36.40 M+47.81%
September 30, 2024
Summary
- As of February 7, 2025, VYGR quarterly cash and cash equivalents is $112.53 million, with the most recent change of +$36.40 million (+47.81%) on September 30, 2024.
- Over the past year, VYGR quarterly cash and cash equivalents has increased by +$43.72 million (+63.55%).
- VYGR quarterly cash and cash equivalents is now -58.06% below its all-time high of $268.32 million, reached on March 31, 2023.
Performance
VYGR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VYGR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -30.5% | +63.5% |
| 3 y3 years | -34.1% | +13.7% |
| 5 y5 years | +46.8% | +13.7% |
VYGR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -41.4% | at low | -58.1% | +72.4% |
| 5 y | 5-year | -41.4% | at low | -58.1% | +72.4% |
| alltime | all time | -41.4% | >+9999.0% | -58.1% | +1499.5% |
Voyager Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $112.53 M(+47.8%) |
| Jun 2024 | - | $76.13 M(-46.8%) |
| Mar 2024 | - | $143.08 M(+108.0%) |
| Dec 2023 | $68.80 M(-30.5%) | $68.80 M(+5.4%) |
| Sep 2023 | - | $65.27 M(-73.3%) |
| Jun 2023 | - | $244.29 M(-9.0%) |
| Mar 2023 | - | $268.32 M(+171.1%) |
| Dec 2022 | $98.96 M(-15.7%) | $98.96 M(+2.2%) |
| Sep 2022 | - | $96.86 M(+23.7%) |
| Jun 2022 | - | $78.33 M(-40.6%) |
| Mar 2022 | - | $131.87 M(+12.3%) |
| Dec 2021 | $117.43 M(+12.4%) | $117.43 M(+5.3%) |
| Sep 2021 | - | $111.47 M(-5.4%) |
| Jun 2021 | - | $117.84 M(+0.0%) |
| Mar 2021 | - | $117.80 M(+12.8%) |
| Dec 2020 | $104.44 M(+21.4%) | $104.44 M(-29.2%) |
| Sep 2020 | - | $147.45 M(+2.2%) |
| Jun 2020 | - | $144.32 M(-12.7%) |
| Mar 2020 | - | $165.23 M(+92.0%) |
| Dec 2019 | $86.04 M | $86.04 M(+4.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $82.64 M(+3.4%) |
| Jun 2019 | - | $79.89 M(-29.5%) |
| Mar 2019 | - | $113.26 M(+141.7%) |
| Dec 2018 | $46.86 M(+48.6%) | $46.86 M(+11.2%) |
| Sep 2018 | - | $42.14 M(-29.3%) |
| Jun 2018 | - | $59.61 M(-57.5%) |
| Mar 2018 | - | $140.37 M(+345.2%) |
| Dec 2017 | $31.53 M(-13.9%) | $31.53 M(-34.6%) |
| Sep 2017 | - | $48.20 M(-27.3%) |
| Jun 2017 | - | $66.30 M(+52.1%) |
| Mar 2017 | - | $43.60 M(+19.0%) |
| Dec 2016 | $36.64 M(+17.0%) | $36.64 M(-42.3%) |
| Sep 2016 | - | $63.51 M(-5.3%) |
| Jun 2016 | - | $67.03 M(+97.8%) |
| Mar 2016 | - | $33.90 M(+8.3%) |
| Dec 2015 | $31.31 M(+345.0%) | $31.31 M(-52.9%) |
| Sep 2015 | - | $66.53 M(-21.5%) |
| Jun 2015 | - | $84.75 M(+1104.7%) |
| Dec 2014 | $7.04 M(+5111.1%) | $7.04 M |
| Dec 2013 | $135.00 K | - |
FAQ
- What is Voyager Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Voyager Therapeutics?
- What is Voyager Therapeutics annual cash & cash equivalents year-on-year change?
- What is Voyager Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Voyager Therapeutics?
- What is Voyager Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Voyager Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of VYGR is $68.80 M
What is the all time high annual cash & cash equivalents for Voyager Therapeutics?
Voyager Therapeutics all-time high annual cash & cash equivalents is $117.43 M
What is Voyager Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, VYGR annual cash & cash equivalents has changed by -$30.16 M (-30.47%)
What is Voyager Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of VYGR is $112.53 M
What is the all time high quarterly cash and cash equivalents for Voyager Therapeutics?
Voyager Therapeutics all-time high quarterly cash and cash equivalents is $268.32 M
What is Voyager Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, VYGR quarterly cash and cash equivalents has changed by +$43.72 M (+63.55%)